research question: What is the individualized bleeding experience of women with fibroids and anaemia in a 3 month randomized placebo controlled trial (PEARL I) of the selective progesterone receptor modulator (SPRM), ulipristal acetate (UPA)?
In those with prolonged, frequent or irregular bleeding there was a high chance that sub-mucous fibroids were present (UPA 5 mg 100% and UPA 10 mg 78.6%) but no correlation with progesterone receptor modulator-associated endometrial changes.
limitations, reasons for caution:
The follow-up PBAC data at Week 26 and Week 38 are only valid for women who did not have surgical intervention. These groups may not be representative of the groups at screening.
wider implications of the findings: This first detailed description of these SPRM bleeding patterns provides clinicians with an indication of potential responses in women using the SPRM UPA and provides an extended definition of bleeding in untreated women with excessive bleeding and fibroids. study funding/competing interest(s): Funded by PregLem/Gedeon Richter. D.H.B. is a member of the Scientific Advisory
Introduction
Uterine fibroids are common tumours of the uterus occurring in 20 -75% of women of reproductive age, depending on the diagnostic method, and they are symptomatic in about half of these women (Baird et al., 2003; Wallach and Vlahos, 2004) . Fibroids are the reason why over 40% of hysterectomies are carried out in the USA with a high cost to the nation (Cardozo et al., 2012) . A common complaint is troublesome and excessive vaginal bleeding and as a result many women have major interventions, such as hysterectomy, myomectomy or uterine artery embolization. There is no long-term effective medical treatment but presurgical use of gonadotrophin-releasing hormone (GnRH) agonists is well established for induction of fibroid shrinkage and control of bleeding (Lethaby et al., 2002) . The levonorgestrel-releasing intrauterine system (LNG-IUS) is effective in some women with fibroids, usually small, but is a contraceptive and therefore not suitable for those wishing to conceive (Gupta et al., 2006; Sangkomkamhang et al., 2013) . More recently, the selective progesterone receptor modulator (SPRM), ulipristal acetate (UPA), has also been shown to induce fibroid shrinkage and control excessive bleeding in randomized controlled trials where the comparator was placebo (PEARL I; Donnez et al., 2012a) or a GnRH agonist (PEARL II; Donnez et al., 2012b) . These two publications presented life table curves for time to achieve control of bleeding and time to achievement of amenorrhoea for each treatment arm and showed that over a 3 month treatment phase a significant majority of the women on 5 or 10 mg/day of UPA indeed achieved not only normalization of bleeding but also amenorrhoea. The responses in terms of bleeding were superior to those of women on placebo (Donnez et al., 2012a) and more rapidly induced than with a GnRH agonist (Donnez et al., 2012b) . Vaginal bleeding in these studies was assessed by means of the validated pictorial blood loss assessment chart (PBAC) tool, which involves daily recording of the vaginal bleeding profile (Higham et al., 1990) . Heavy menstrual bleeding (HMB) is defined as a score above 100 during the 8 days of menstrual bleeding.
'Normalization' of bleeding was defined as heaviness similar or less than the average bleed for a normal population, which is a PBAC score of 75 or less. The rates of normalization of bleeding on UPA at 3 months (calculated for the previous 28 days) in PEARL I were 91.5% (UPA 5 mg), 92.5% (UPA 10 mg) and 18.8% (Placebo), and in PEARL II they were 90.3% (UPA 5 mg), 97.9% (UPA 10 mg) and 89.1% (GnRH agonist). The amenorrhoea rates at 3 months in PEARL I were 73.4% (UPA 5 mg), 81.7% (UPA 10 mg) and 6.3% (Placebo), and in PEARL II they were 75.3% (UPA 5 mg), 89.5% (UPA 10 mg) and 80.4% (GnRH agonist; Donnez et al., 2012a,b) . In smaller studies achievement of amenorrhoea has been reported for 32 -41% for mifepristone and for 16 -70% for asoprisnil (Fiscella et al., 2006; Chwalisz et al., 2007; Bagaria et al., 2009) .
The design of the PEARL I and PEARL II studies involved PBAC assessment during both an untreated screening cycle and 3 months on 'treatment'. Moreover, clinicians have no previous exposure to the extended use of an SPRM in gynaecology. Therefore, the detailed bleeding assessment enables us to provide, for the first time, a clinically helpful systematic description of the individual patient experience that looks behind the mean data in sufficient detail that it can be used to guide the expectations of individuals. In addition, by focussing on PEARL I in which the control group received placebo, there is the opportunity to report in detail the untreated bleeding experience of a large group of women with troublesome fibroids recorded systematically over a timespan of months.
The meaningful classification of patterns of vaginal bleeding in individuals where there is deviation from regular periods has long been recognized to be challenging. Classification has been of great interest in the study of the effects of therapies, such as those used in hormonal contraception. The problem was addressed by WHO and a practical classification was published in Belsey et al. (1986) . Although modification of this scheme has been discussed (Fraser, 1994) , the original WHO classification remains in current use (Jensen et al., 2013) . This paper uses the WHO classification to define the experience of women with anaemia related to excessive bleeding associated with fibroids in the PEARL I study. This provides the opportunity to examine the individualized experience of untreated women (the placebo group). Their predominant pattern of bleeding might be expected to be regular heavy periods, and this can be compared with that of women treated with UPA in whom the mean population data suggest relief for excessive bleeding but for whom there are no published data on individualized bleeding patterns. PRMs lead to unique changes in the endometrium, which are not hyperplastic although cystic change is common. These patterns differ from those of the Noyes classification used to assess endometrium during the normal menstrual cycle and on sex steroids. These changes are described as PRM-associated endometrial changes (PAEC; Mutter et al., 2008; Williams et al., 2012) , and are thought to be rapidly reversible. Currently available data provide reassurance for the short-term safety of SPRM; clinical trials assessing long-term safety of PRMs and the endometrial changes are currently ongoing.
Materials and Methods

Design and patients
The PEARL I study design for this double-blind placebo-controlled randomized clinical trial is provided in detail in the primary publication (Donnez et al., 2012a) . The study was carried out in centres in Europe and India and involved women, 18-50 years old, with uterine fibroids who were judged to have a sufficient problem to justify hysterectomy or myomectomy, and the plan would be for 3-months of treatment leading up to the surgery. Patients needed to have uterine fibroids with at least one of diameter ≥3 and ,10 cm (assessed by ultrasonography); uterine size no ≥16 weeks pregnancy, and excessive menstrual bleeding (quantified by a PBAC . 100 during the first 8 days of the menstruation in the screening period) resulting in an anaemic status with a haemoglobin level of ≤10.2 g/dl. Women with known severe coagulation disorders were excluded from study participation. The design involved randomization to three treatment arms, namely placebo, UPA 5 mg daily or UPA 10 mg daily with allocation in the ratio 1:2:2. All women received 80 mg/day oral iron during the active treatment phase. The treatment duration was 13 weeks with the active treatment or placebo initiated in the first 4 days of the start of a period, normally the first period after the screening cycle. The co-primary study end-points were uterine fibroid shrinkage measured by a centralized MRI, which has been reported, along with the mean population experience of bleeding in terms of the percentages achieving normalization of bleeding (PBAC for 28 days preceding Week 13 , 75; Donnez et al., 2012a) . All patients were followed up over a period of 6 months after end of treatment. Women who had not undergone hysterectomy were requested to report at two time points the menstrual bleeding pattern over a period of 28 days preceding visits at Week 26 and Week 38. Concomitant medication, which might interact with the bleeding profile, was prohibited over the length of the study. The record of concomitant medications showed that the only drug that was taken by participants that might have an impact on bleeding was ibuprofen. It was taken at some point by eight women during the treatment phase (5 on UPA 5 mg, 1 on UPA 10 mg and 2 in the placebo group). In the post-treatment phase, it was taken by one woman from the UPA 5 mg group. Donnez et al. (2012a) provides a detailed presentation of the treatment group demographics and shows that they were balanced. In brief, there were 48 women in the placebo group; 95 women in the UPA 5 mg group and 94 women in the UPA10 mg group. The mean ages were in the range 41242 years, mean BMI was 24.6225.9 and 85290% were white with 10215% Asian.
Assessment of menstrual bleeding by PBAC
PBAC is a validated self-reporting tool for assessing menstrual blood loss (Higham et al., 1990; Zakherah et al., 2011) and has been used for the evaluation of many interventions in the management of HMB (Busfield et al., 2006; Gupta et al., 2006; Kouides et al., 2009; Abu Hashim et al., 2012) . Higham et al. (1990) describe blood losses over the entire range including in women who did not complain of HMB (some were as low as 20 ml). The overall correlation of PBAC with the 'gold standard' alkaline haematin was 0.847 with greater variability over a score of 200.
The women recorded daily the number of tampons and towels used and the degree to which individual items were soiled with blood on a chart, which provided a visual reference for the amount of blood spoiling that had taken place. For example, a slightly stained tampon/towel scores 1 whilst a tampon completely saturated with blood scores 10 and a towel completely saturated with blood scores 20. HMB is defined as a PBAC . 100 during one menstrual period, which approximates to a blood loss of .80 ml. A PBAC of 400 corresponds to a blood loss of around 300 ml or 80 tampons/towels used. Patients were asked to complete the PBAC daily throughout the 13-week treatment phase.
Classification of individual bleeding profiles
The daily PBAC profile available for each woman included (a) an untreated screening cycle commencing with a period (Ps), (b) the period (P1) at the start of which the UPA or placebo was initiated and (c) the remainder of the 3-month 'treatment' phase following the cessation of P1. For the aim of this publication, further periods occurring during this phase were designated P2, P3 and P4. It was appreciated that, depending on cycle length, some women might not have reached the bleed designated as P4 by Week 13.
The definitions used in classifying the vaginal bleeding patterns were based on Belsey et al. (1986) . This scheme was developed under the auspices of the WHO. These definitions have been widely used in studies of 3 months duration. Where bleeding was likely to be due to menstruation, as in the placebo group throughout the study and for the UPA groups at Screening (Ps) and treatment initiation period (P1), the definition of the duration a period was taken to permit a 1-day bleed-free gap within the period. However, a 2-day or greater bleed-free interval was taken to denote the end of a specific period (Fraser, 1994) . All profiles were studied and classified by one of the gynaecologist authors (D.H.B.) and the allocation confirmed by another gynaecologist author (M.A.L.). The classification is shown in Table I and the distribution of the classified patterns in the study groups is shown in Table II .
Since individual distress due to bleeding might reflect not only the temporal pattern but also the volume of blood lost (the menstrual blood loss or MBL), the women in the WHO categories were divided where appropriate to indicate whether the blood loss over the 3 months was very low. An arbitrary level of PBAC of 60 for the whole 3-month period of study was taken as an indicator of potentially acceptable blood loss in a group of women who had been experiencing heavy blood loss prior to treatment. This categorization is indicated in Table III .
Some women did not go on to have a hysterectomy and follow-up data are available at Week 26 and Week 38 post-treatment. The PBAC was completed once again for the 28 days that preceded these time points. Information is also available regarding the timing of surgery since some women went on to hysterectomy between Week 26 and Week 38. Fibroid size for inclusion purposes was assessed at screening by ultrasound scanning for all participants. Over 90% also had an MRI scan at recruitment and again after completing treatment, and this provided information on fibroid position. The relationship of sub-mucous fibroid location and bleeding patterns was explored for this paper. Endometrial biopsies were taken before and after treatment and PAEC data in relation to bleeding patterns were also considered.
Results
Patients
Patient flow through enrolment, treatment allocation and follow-up is shown in Fig. 1 .
Representation of bleeding by median and mean data
The comparative bleeding experience of the three groups of PEARL I over the 3 months treatment phase may be represented by mean or median profiles as is presented in Fig. 2 where the profiles are aligned to the first day of the period at which treatment was initiated. After the menstruation at which treatment was initiated, the daily PBAC profiles presented as median data (Fig. 2a) indicate the clear difference between the placebo group, in which subjects continued to have monthly periods, and the UPA groups in which the median profiles indicate absence of bleeding for the majority of women. When the daily PBAC profiles are presented for the three groups as means (Fig. 2b) , the UPA profiles indicate that some UPA-treated women still had menstrual bleeding, and since this ranged from minimal bleeding to more significant bleeding for some it is valuable to define this experience on an individual basis.
Graphic presentation of individual bleeding profiles
Presentation of the daily PBAC data by the graphic representation of each woman's profile as an individual line on a composite graph gives a more informative picture of the experience on UPA and the comparators. Figure 3 presents the profile of bleeding across the 13 weeks in terms of daily PBAC scores of the individual women with each woman represented by a single line based on the intention-to-treat (ITT) population. The greater intensity of bleeding experienced by women on placebo (Fig. 3a) across the whole 13 week treatment phase is seen compared with the UPA 5 mg and 10 mg groups ( Fig. 3b and c, respectively) .
Classification of individual patient PBAC profiles
The distribution of the different patterns of bleeding experience by individual women in PEARL I, based on the ITT population, is shown in Table II . The major difference between the groups is the predominance of regular menstruation in the placebo group (81.3%) and the predominance of amenorrhoea or amenorrhoea plus minor spotting in the UPAtreated groups (63.2% UPA 5 mg; 71.3% UPA 10 mg).
The placebo group in detail
The examination of profiles in the placebo group of 48 women provides detailed information on the sequential untreated bleeding experience of a series of women with HMB in association with fibroids sufficient to cause anaemia. For the placebo group, patterns other than regular menstruation were uncommon, with irregular bleeding the most commonreported by 8% and infrequent bleeding by 6% (Table II) .
Screening cycles
For all of the 48 women in the placebo group, the screening cycles involved a discrete menstruation which varied in duration from 4 to 17 days with only five women having bleeding of greater duration than 9 days at 10, 10, 11, 12 and 17 days. The median duration of bleeding was 7.1 days and the interquartile range (IQR) was 5-8 days. With the context that a PBAC for a menstruation .100 is taken to be excessive and a PBAC of 100 being an inclusion criterion for the study, the range The classification describes the bleeding/spotting experience beyond the cessation of the treatment initiation period [the end of the treatment initiation period (P1) was defined as two consecutive bleed-free days. Two women on UPA 5 mg and one woman on UPA 10 mg bled throughout the first 28 days from the start of the treatment initiation period] over the treatment phase of 13 weeks. PBAC, pictorial blood loss assessment chart.
of PBAC for the screening period (Ps) was 119-1284. The median PBAC was 376 (IQR 241 -574).
Treatment phase
The predominant experience of the placebo group (39 women, 81.3%) was regular menstrual bleeding. For this subgroup, the median (IQR) total PBAC scores for P1, P2 and P3 were similar to the screening period (Ps). The results were Ps 351 (234-575); P1 294 (181 -442); P2 325 (170-532) and P3 342 (166-612). Compared with mean Ps PBAC score as 100%, the mean scores calculated for each woman then averaged were 89.8% (P1), 92.4% (P2) and 93.1% (P3). On an individual basis there was some noticeable variation between intensity of the series of untreated periods but the Spearman Rank Correlation coefficients indicated some consistency between cycles, namely 0.60; 0.70 and 0.67 (all P values ,0.0001) for P1, P2 and P3 versus Ps. This is consistent with studies of large populations of regularly cycling women (Rybo, 1966) . Within this group of 39 women with regular menstruation, four had quite marked spontaneous improvement on placebo. These are worth describing in terms of the total PBAC score for the consecutive periods commencing with the screening period (Ps), then the initiation period P1 and through to P3, and P4 in two cases. The total PBAC profiles were (119-121-18-27-31); (171-248-21-8); (216-271-77-84-33); (672-144-131-64) .
Although she received no active treatment, one woman of the placebo group had no bleeding after cessation of the initiation period. In screening the woman had a 6 day menstrual period scoring a PBAC of 1230; her P1 period was only 1 day scoring PBAC 12 then no further bleeding occurred. Case review indicated that she was entering a menopausal transition. She was 48 years of age and screening FSH was 88.2 and 33.8 at the end of treatment.
Follow-up phase
All women in the study were eligible for surgery but many women opted to postpone or cancel surgery. As a result there are follow-up data at Week 26 and Week 38 after the treatment start for those who did not have surgical intervention (hysterectomy, myomectomy or Uterine Artery Embolization). During follow-up iron was given at the discretion of the treating physician. For this subgroup of the placebo group there are Week 26 PBAC data on 22 women and Week 38 PBAC data on 21 women. The median total PBAC for the 28 days preceding Week 26 was 312 (IQR 102-524) and was 236 (IQR 103-465) for Week 38. From the 39 women of the placebo group with regular periods described above 18 women did not have surgery. For these women the median total PBAC for the 28 days was 312 (IQR 102-446) at 26 weeks and 236 (IQR 139-371) at 38 weeks. For these women it was possible to describe their profile of mean total PBAC for menstruations P1, P2, P3 and P26 and P38; all expressed as a percentage of the screening menstruation Ps. The results were 93.1% (P1), 83.1% (P2), 88.4% (P3), 71.3% (P26) and 62.2% (P38).
UPA groups in detail
The predominant experience of the 95 women who were treated using UPA 5 mg and the 94 women who received UPA 10 mg was a major improvement in bleeding. Mean PBAC data for the treated groups has been reported (Donnez et al., 2012a) but these are too global to enable clinicians to provide guidance on the prevalence of the bleeding patterns experienced on treatment. The classification of the individualized bleeding patterns is summarized in Table II .
Screening cycles
Two women in each of the two UPA groups had prolonged bleeding through most or all of the screening cycle and 93 (UPA 5 mg) and 92 (UPA 10 mg) screening cycles involved a discrete period. For the women with discrete periods these varied in duration from 2-19 days (UPA 5 mg) or 4-15 days (UPA 10 mg). For both groups the median duration of bleeding was 7 days (IQR 6-8). The range of PBAC for the women with a discrete screening period (Ps) was 118-1645 (UPA 5 mg) and 102-1570 (UPA 10 mg). The median PBAC for the screening 
Table III
Classification of patterns of spotting/bleeding (Sp/Bld) in PEARL I comparing women experiencing a total PBAC score of more than, versus less than, 60 over the whole 13 week treatment episode, excluding the period in which treatment was initiated.
Belsey classification (see Table I periods of the UPA 5 and 10 mg groups, respectively, were 358 (IQR 232-621) and 330 (IQR 235 -542).
Treatment phase
The impact of the UPA was that none of the women maintained regular periods and a majority had rapid relief from their excessive menstruation by entering amenorrhoea with the ending of the period (P1) in which the UPA was commenced (Table II) . Overall 63.1% of the UPA 5 mg group and 71.3% of the UPA 10 mg group had amenorrhoea or only very minimal spotting amounting to less than a total PBAC of ,12 for the whole treatment phase. The other patterns of bleeding were less common: 'infrequent bleeding' (17.9% UPA 5 mg; 12.8% UPA 10 mg); 'frequent' or 'prolonged' bleeding or both (12.7% UPA 5 mg; 11.7% UPA 10 mg) and 'irregular' bleeding (5.3% UPA 5 mg; 3.2% 10 mg). Although amenorrhoea, or near amenorrhoea, might be considered to be an optimal bleeding response for women with excessive vaginal bleeding it is valuable to estimate the extent to which women with other bleeding patterns are likely to have experienced a major impact on their excessive loss. These women had become anaemic and their PBAC in the screening menstruation (Ps) was in excess, or greatly in excess, of 100; the upper limit of 'normal' for a single menstruation. On that basis, in Table III there is an estimate of the numbers of women whose blood loss under therapy was quite light and who were likely to have experienced major relief of their distress from heavy bleeding. For this purpose, we arbitrarily defined significant relief as a total PBAC , 60 for the whole 13 week treatment phase excluding the bleed (P1) at treatment initiation which approximates to an average monthly PBAC of ,20.
As shown in Table III , 34 women on UPA 5 mg and 27 women on UPA 10 mg experienced infrequent, frequent, irregular or prolonged bleeding and 13 of the 34 women on UPA 5 mg (38.2%) and 9 of the 27 on UPA 10 mg (33.3%) had a total PBAC , 60. Taking these together with the women who developed amenorrhoea or had only minimal spotting, 77.7% of women on UPA 5 mg and 80.9% of those on UPA 10 mg are very likely to have benefited in terms of bleeding in the time following on from P1. However, such mild but irregular and prolonged bleeding Uterine fibroids and vaginal bleeding in PEARL I will be considered as unacceptable by some women as is seen in users of progestogen-only contraception.
Follow-up
Follow-up PBAC data, off treatment, are available for those women who had not had surgical intervention. The follow-up information describes the PBAC assessments of the 28 days preceding Week 26 and Week 38. In the UPA 5 mg group, there are follow-up PBAC data on 48 women at Weeks 26 and 38. In the UPA 10 mg group, there are followup PBAC data on 38 and 35 women at Weeks 26 and 38, respectively. For the UPA 5 mg group, the median PBAC scores were 235 (IQR 88-371) at Week 26 and 187 at Week 38. These represent 84.0 and 78.1% of the baseline PBAC values for the same 48 women. For the UPA 10 mg group, the median PBAC scores were 215 (IQR 132-343) at Week 26 and 157 (IQR 45-302) at Week 38. These represent 138.9 and 58.7% of the baseline PBAC values for the 38 and 35 women.
The influence of sub-mucous fibroids on individualized bleeding patterns on therapy
At baseline, prior to the commencement of treatment, 50.9% of the women were noted to have sub-mucous fibroids by MRI assessment.
The impact of sub-mucous fibroids on the bleeding patterns is shown in Table IV. In the placebo group, three of four women with an abnormal pattern likely to have an adverse impact on the patient (prolonged, frequent or irregular bleeding) had sub-mucous fibroids. With 5 mg UPA all 16 women with these bleeding patterns had sub-mucous fibroids and with 10 mg UPA the result was 11 of 14. In the overall population of UPAtreated women those without evidence of sub-mucous fibroids were very unlikely to have prolonged, frequent or irregular bleeding under treatment, 3 of 92 women (3.3%) compared with 27 of 91 women (29.7%) who had sub-mucous fibroids. This suggests that the presence of sub-mucous fibroids is associated with failure of women on UPA treatment to have either 'no bleeding' or 'irregular bleeding'.
It is important that in the counselling of women with fibroids being considered for UPA treatment that it is explained that whilst the presence of sub-mucous fibroids raises the risk of bleeding on treatment compared with fibroids in other locations there are many women with sub-mucous fibroids who are not troubled by bleeding on treatment. No bleeding was the outcome in 23 of 51 (45.1%) and 25 of 40 (62.5%) of women with sub-mucous fibroids on UPA 5 mg and 10 mg, respectively, and combining no bleeding or infrequent bleeding (with only one to two bleeding episodes over the observation period) as outcomes the equivalent proportions were 35 of 51 (68.6%) and 29 of 40 (72.5%).
The influence of PAEC on individualized bleeding patterns on treatment PAEC were reported in 3 of 38 (7.9%) women on placebo, 58 of 78 (74.4%) of women on 5 mg UPA and 57 of 78 (73.1%) of women on 10 mg UPA (total 115 of 156 or 73.7%; Table V) . For all UPA-treated women 80 of 115 (69.6%) with PAEC and 28 of 41 (68.3%) without PAEC had no bleeding. In those with prolonged, frequent or irregular bleeding 23 of 28 (82.1%) treated with UPA had PAEC but it is notable that 21 of these cases also had sub-mucous fibroids.
Discussion
In the management of uterine fibroids, as in the management of women with HMB the impact of the therapy on the woman's experience of bleeding in terms of the pattern of the bleeding and the volume of blood loss will be important in determining patient satisfaction with any intervention. Although progestogens are widely used to treat HMB The data shown are for women who had magnetic resonance imaging (MRI) and percentages were calculated within treatment group. For seven women (placebo n ¼ 1; UPA 5 mg n ¼ 2; UPA 10 mg n ¼ 4) no MRI data were available and these women were not included in the Belsey classification (see Table I Percentages given are of those who had PAEC yes/no within treatment group. No PAEC data were available for some women where the biopsy sample was inadequate or there was no biopsy (placebo n ¼ 10; UPA 5 mg n ¼ 17; UPA 10 mg n ¼ 16). Sp/Bld, spotting/bleeding; PBAC, pictorial blood loss assessment chart.
in women who have fibroids and also those who have no obvious pathology, the 'gold standard' in the UK and Europe for women with normal uteri is the LNG-IUS. This has been shown to be cost-effective at 1 year although it is unsuccessful in 30% of women by 5 years when its advantages compared with hysterectomy decrease significantly. The reasons for failure are that it is less successful in the presence of fibroids. Moreover, irregular bleeding is extremely common and may continue for many months, which is a common reason for the device to be removed (Sangkomkamhang et al., 2013) . For a large proportion of women, the predominant experience with the use of UPA to manage uterine fibroids is the rapid onset of amenorrhoea or near amenorrhoea. However, it is important to understand the bleeding patterns in those who do not have this experience as even though the bleeding may be significantly decreased, as with the LNG-IUS, this may not be satisfactory for women in the longer term if there is ongoing irregular bleeding. Understanding the individualized experience of bleeding facilitates consideration of aggravating factors and better counselling of women on what to expect on treatment with UPA. This may be a key element for optimizing women's satisfaction with treatment.
To put the findings with UPA into context, the data with placebo should be carefully considered. It is of interest that irregular bleeding was uncommon, fibroids being listed as one of the main benign pathologies to lead to this problem. A majority of women complained of regular, heavy periods although an HMB with a PBAC . 100 was an inclusion criterion. The correlation between one period and the next in the same women is good as has been demonstrated in the studies performed in populations of women in Scandinavia and the UK (Halberg and Nisson, 1964; Rybo, 1966) . This would suggest that women with fibroids who have heavy periods are unlikely to notice much change from one period to the next and this is likely to have resulted in the anaemia.
Women were not excluded if they also had irregular bleeding as well as HMB. Ultrasound information on fibroids defined inclusion in the study but additionally the site of the fibroids was assessed by centralized MRI and is available on all but seven women. However, that being said, in the placebo group irregular bleeding occurred in only 4 (8%) women and this was not confined to those with sub-mucous fibroids (Table IV) suggesting a different aetiology, which is currently unknown. Of interest is that the MBL decreased during both the treatment period and during the follow-up. One woman on placebo had become amenorrhoeic during the placebo treatment phase and one by 26 and 38 week follow-up. Four noted a considerable decrease in menstrual bleeding and five had surgical treatment resulting in amenorrhoea.
UPA resulted in a completely different profile. There was a high rate of amenorrhoea on treatment and assuming this would continue with longer-term administration, this is likely to be a satisfactory result for the women. While 80% of women are likely to gain a clinically meaningful effect from UPA on their bleeding distress, 20% of women are likely to consider their outcome as not entirely satisfactory. This is because there was significant bleeding leading to a PBAC . 60 over 3 months (corresponding to an effective average monthly PBAC of 20 or more), or there was irregular bleeding which can be extremely irritating, even if light as has been demonstrated with the LNG-IUS. Irregular bleeding with UPA was more likely in women with sub-mucous fibroids. This is not surprising and has been discussed previously in the literature (Munro et al., 2012) . The likelihood of the presence of ongoing, irregular bleeding will be important information for clinicians and women considering this treatment. The observation that in a proportion of women SPRM therapy is associated with a variety of patterns of irregular bleeding parallels the well-recognized occurrence of irregular bleeding in a proportion of women treated with progestogen-only therapies in gynaecology.
The assessment of bleeding during the follow-up period is difficult to evaluate. Concomitant medication interfering with menstrual blood loss was prohibited during the entire study and the record of concomitant medication revealed that in the post-treatment phase only one woman, from the UPA 5 mg group, used ibuprofen. Women having undergone a hysterectomy were excluded from the bleeding assessment. Decreased blood loss does persist in some women as with placebo and it is probable that this is the reason why some women avoided further treatment, although not only those with the heaviest loss proceeded to further intervention. However, predicting who will have this decreased loss is not possible on the available data. It is of interest that 19/38 women in the placebo group did not proceed to surgery and continued to menstruate regularly, and other factors, e.g. presence of other fibroid-related symptoms will be of importance.
Biopsy was reported as PAEC in three women on placebo and in a significant proportion of those having UPA and, even though current assessments regard these as benign changes, the natural history of their resolution off treatment and the long-term implications of repeated UPA exposure remains to be resolved by further studies. It is also important that pathologists interpreting endometrial biopsies from UPAtreated women recognize the features of PAEC so that misdiagnosis is avoided. Whilst 69.6% of women having PAEC on treatment with UPA had 'no bleeding' it is notable that in those with prolonged, frequent or irregular bleeding 82.1% were found to have PAEC at the end of treatment. There was no relationship between bleeding pattern and the presence of PAEC.
UPA is an exciting preparation that offers additional choice to women with fibroids. It is administered orally, which is an advantage over an IUS although additional contraception is required while it is being taken. It improves the bleeding profile in 80% of women and is well tolerated with fewer side effects than GnRH agonists, the licensed alternative for pre-operative use. There may also be the possibility of a carry-over effect in some women although it is difficult to predict who these will be. Studies of longer term use with a discontinuous regimen are underway and may provide novel opportunities for extended use of the drug. This is the first detailed dissection of the effects of UPA in women with significant uterine fibroids providing the necessary understanding for clinicians on what to expect in UPA management of fibroids. These data relate to the effects of a single 3 months UPA treatment prescribed before surgery and it is important that longer-term treatment studies, currently being conducted, further extend our understanding of the potential effects of UPA treatment in women with uterine fibroids. P.T.: statistician and manuscript review. E.B.: study design and manuscript review.
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